Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
Previous PostParticipation terms in the Combined General Meeting
Next PostMedincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting